Optiscan Imaging (ASX:OIL) has entered into a collaboration through a know-how agreement with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system for use in robotic surgery.
The collaboration combines Optiscan’s engineering expertise in digital endomicroscopic hardware and software development with Mayo Clinic’s know-how in robotic surgery and quality patient care.
The agreement, which covers a 24-month co-development plan, will bring together experts from both companies to develop a robot-compatible endomicroscopic imaging system with an initial focus on robotic-assisted breast cancer surgery.
“We’re excited to collaborate with Mayo Clinic to accelerate the development and clinical testing of our robotic imaging platform with the aim of fast-tracking the adoption of real-time digital pathology and image- guided precision robotic surgery,” Optiscan CEO and Managing Director, Dr Camile Farah, said.
“This collaboration is built on a shared history of innovation and a laser focus on delivering the highest quality patient outcomes for better health care delivery.”
Mayo Clinic is the largest integrated, not-for-profit medical group practice in the world, focussed on transforming health care and building a healthier world. Its drive to deliver better medical care has earned it more top rankings for high-quality patient care than any other health care organization. It has more #1 rankings than any other hospital in the US and is top-ranked in more specialties than any other US hospital.
The hospital undertakes more than 141,000 surgical cases and performs more than 4,000 robotic surgery cases a year.
The robotic-assisted surgery market is experiencing significant growth and is expected to continue expanding driven by technological advancements, increasing adoption, rising prevalence of chronic diseases, an aging population, surgeon demand, and favourable reimbursement policies. The US robotic surgery service market was valued at US$1.8 Bn in 2022 and is estimated to grow at a compound annual growth rate (CAGR) of 17.3% to reach US$6.4 billion in 2030.
“The collaboration is part of Optiscan’s wider strategic focus on the US market, and its plan to embed its platform technology as a key component of intraoperative oncological surgery workflows in a variety of settings and clinical applications to provide surgeons with real- time microscopic information of cancer clearance for the potential to reduce missed cancers and minimise repeat surgeries due to residual disease,” Dr Farah added.
